(Q36928318)

17 August 2017

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia (English)

1 reference

17 August 2017

1 reference

10

Robert K Stuart

1 reference

17 August 2017

12

Martin S Tallman

1 reference

17 August 2017

Frederick R. Appelbaum

series ordinal

14

object named as

Frederick R Appelbaum

1 reference

17 August 2017

1

Stephen H Petersdorf

1 reference

17 August 2017

7

Richard A Larson

1 reference

17 August 2017

4

Cheryl Willman

1 reference

17 August 2017

11

Roland B Walter

1 reference

17 August 2017

3

Marilyn Slovak

1 reference

17 August 2017

6

Joseph Brandwein

1 reference

17 August 2017

8

Harry P Erba

1 reference

17 August 2017

9

Patrick J Stiff

1 reference

17 August 2017

13

Leif Stenke

1 reference

17 August 2017

Kenneth J Kopecky

2

1 reference

17 August 2017

Thomas Nevill

series ordinal

5

1 reference

17 August 2017

language of work or name

English

0 references

publication date

16 April 2013

1 reference

17 August 2017

1 reference

17 August 2017

121

1 reference

17 August 2017

24

1 reference

17 August 2017

4854-4860

1 reference

Gemtuzumab ozogamicin: time to resurrect?

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Anthracycline dose intensification in acute myeloid leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682338

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

4 September 2018

1 reference

12 December 2020

Expression of normal myeloid-associated antigens by acute leukemia cells

1 reference

12 December 2020

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia

1 reference

12 December 2020

Outcomes and quality of care in acute myeloid leukemia over 40 years

1 reference

12 December 2020

10.1182/BLOOD-2013-01-466706

Identifiers

DOI

1 reference

17 August 2017

1 reference

17 August 2017

1 reference